Volume | 4,640 |
|
|||||
News | - | ||||||
Day High | 0.70 | Low High |
|||||
Day Low | 0.5601 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Regen Biopharma Inc (PK) | RGBP | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.57 | 0.5601 | 0.70 | 0.5701 | 0.685 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
18 | 4,640 | $ 0.59731 | $ 2,772 | - | 0.401 - 2.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:53:27 | 775 | $ 0.5701 | USD |
Regen Biopharma Inc (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.24M | 3.38M | - | 77k | -1.73M | -0.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Regen Biopharma (PK) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGBP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.70009 | 0.72 | 0.549975 | 0.6951386 | 1,893 | -0.12999 | -18.57% |
1 Month | 0.695 | 0.76 | 0.54 | 0.6451674 | 4,880 | -0.1249 | -17.97% |
3 Months | 0.77 | 0.935 | 0.401 | 0.7170793 | 11,533 | -0.1999 | -25.96% |
6 Months | 1.40 | 1.50 | 0.401 | 0.8190658 | 17,914 | -0.8299 | -59.28% |
1 Year | 2.40 | 2.40 | 0.401 | 1.11 | 12,859 | -1.83 | -76.25% |
3 Years | 25.95 | 122.25 | 0.401 | 30.67 | 29,946,849 | -25.38 | -97.80% |
5 Years | 1.50 | 122.85 | 0.0015 | 25.38 | 46,756,249 | -0.9299 | -61.99% |
Regen Biopharma (PK) Description
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com. |